Recent News Releases
CSL Appoints New Directors
Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018.
New National Fractionation Agreement
CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and secure supply of plasma-derived therapies manufactured in Australia.
Expansion of CSL Biotech Facility
CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.
CSL and Vitaeris Strategic Partnership
Agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.
CSL112 Phase 3 Clinical Trial
The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world.
CSL Behring Australia
Senior Manager, Communications
Phone: +61 429 609 762